Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,594
Out of 4,609 analysts
332
Total ratings
29.8%
Success rate
-16.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintained: Buy | $12 → $15 | $6.34 | +136.59% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $24.48 | +132.84% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $14.21 | +244.83% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $7 → $13 | $11.24 | +15.66% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $7 → $9 | $1.97 | +356.85% | 23 | Apr 14, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $47 → $40 | $25.82 | +54.92% | 12 | Feb 13, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $7.28 | -3.85% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Maintained: Buy | $8 → $1 | $0.3059 | +226.90% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Maintained: Buy | $64 → $46 | $23.70 | +94.09% | 29 | Dec 23, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $52 → $44 | $51.64 | -14.79% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.13 | +342.48% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $2.90 | +106.90% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.13 | n/a | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4 | $2.49 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0025 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.00 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $34.50 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.69 | n/a | 26 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $72 → $65 | $61.46 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $27 | $16.20 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $12.12 | n/a | 9 | Sep 26, 2023 |
Taysha Gene Therapies
Jun 30, 2026
Maintained: Buy
Price Target: $12 → $15
Current: $6.34
Upside: +136.59%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $24.48
Upside: +132.84%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $14.21
Upside: +244.83%
Intellia Therapeutics
Apr 27, 2026
Maintained: Hold
Price Target: $7 → $13
Current: $11.24
Upside: +15.66%
Allogene Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $7 → $9
Current: $1.97
Upside: +356.85%
Ultragenyx Pharmaceutical
Feb 13, 2026
Maintained: Buy
Price Target: $47 → $40
Current: $25.82
Upside: +54.92%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $7.28
Upside: -3.85%
Mereo BioPharma Group
Dec 29, 2025
Maintained: Buy
Price Target: $8 → $1
Current: $0.3059
Upside: +226.90%
Vor Biopharma
Dec 23, 2025
Maintained: Buy
Price Target: $64 → $46
Current: $23.70
Upside: +94.09%
CRISPR Therapeutics AG
Nov 11, 2025
Maintained: Hold
Price Target: $52 → $44
Current: $51.64
Upside: -14.79%
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.13
Upside: +342.48%
Aug 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $2.90
Upside: +106.90%
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $3.13
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $5 → $4
Current: $2.49
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0025
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $11.00
Upside: n/a
Nov 6, 2024
Maintained: Buy
Price Target: $84
Current: $34.50
Upside: n/a
Nov 5, 2024
Maintained: Buy
Price Target: $10
Current: $2.69
Upside: n/a
Oct 30, 2024
Maintained: Hold
Price Target: $72 → $65
Current: $61.46
Upside: n/a
Nov 16, 2023
Maintained: Hold
Price Target: $27
Current: $16.20
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $12.12
Upside: n/a